The Fund aims to achieve capital growth.
Name | % Net Assets |
---|---|
GlaxoSmithKline PLC | 5.8% |
BG Group PLC | 4.9% |
AstraZeneca PLC | 4.2% |
Royal Dutch Shell PLC | 3.9% |
HSBC HLDGS | 3.6% |
BRITISH AMERICAN TOBACCO | 3.6% |
Imperial Tobacco Group PLC | 3.5% |
British American Tobacco PLC | 3.3% |
Wolseley PLC | 2.9% |
Legal & General Group PLC | 2.9% |
Key | % Net Assets |
---|---|
GlaxoSmithKline PLC | 5.8% |
BG Group PLC | 4.9% |
AstraZeneca PLC | 4.2% |
Royal Dutch Shell PLC | 3.9% |
Other | 81.2% |
Date | 01-Mar-2024 |
---|---|
NAV | 132.22p |
Currency | GBP |
Change | 0.76p |
% | 0.58% |
YTD change | -1.85p |
YTD % | -1.38% |
Fund Inception | 31/05/1976 |
---|---|
Fund Manager | Chris White |
TER | 1.56 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.05 |
You are here: research